Soleno TherapeuticsNASDAQ: SLNO

Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects.

Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.

The company's Prader-Willi treatment inched closer to FDA approval.

SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.

REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) ("Soleno") on behalf of the company's stockholders. The investigation seeks to determine whether Soleno and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

The FDA has given Breakthrough Therapy Designation to diazoxide choline, which is significant for Soleno as it will speed up the review process for their main candidate.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.